A steroid-sparing strategy for IgG4-related disease: lenalidomide put to the test
NCT ID NCT07719543
First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time
Summary
This phase III trial tests whether lenalidomide, an immune-modulating drug, can prevent disease flares in people with IgG4-related disease who are in remission. Participants receive either lenalidomide or a placebo for 52 weeks while tapering off steroids. The goal is to see if lenalidomide reduces relapse risk and allows patients to avoid long-term steroid side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- lenalidomide
- What this could lead to
- If it works, lenalidomide could offer a steroid-sparing maintenance option for people with IgG4-related disease, lowering relapse risk and side effects from long-term steroid use.
- What could go wrong
- This is a phase III trial, but lenalidomide has known risks including blood clots, low blood counts, and infections. It may not prove better than placebo at preventing relapses.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOGLOBULIN G4-RELATED DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
General Hospital of Central Theater Command
Wuhan, Hubei, 430070, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
-
Hainan Hospital of Chinese PLA General Hospital
Sanya, Hainan, 572013, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
-
The First Medical Center of Chinese PLA General Hospital
Beijing, Beijing Municipality, 100853, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.